 Connection
Elizabeth Pomfret to Cell Line, Tumor
This is a "connection" page, showing publications Elizabeth Pomfret has written about Cell Line, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.091 |
|
|
|
-
Ma J, Wang Z, Mintzlaff D, Zhang H, Ramakrishna R, Davila E, Witkowski MT, Lucia MS, Schwartz MS, Pomfret EA, Mathes DW, Wang Z. Bivalent CD47 immunotoxin for targeted therapy of T-cell acute lymphoblastic leukemia. Blood. 2025 Jan 30; 145(5):508-519.
Score: 0.035
-
Qiu Y, Qi Z, Wang Z, Cao Y, Lu L, Zhang H, Mathes D, Pomfret EA, Lu SL, Wang Z. EGF-IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models. Oncol Rep. 2023 Feb; 49(2).
Score: 0.030
-
Qi Z, Qiu Y, Wang Z, Zhang H, Lu L, Liu Y, Mathes D, Pomfret EA, Gao D, Lu SL, Wang Z. A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma. Mol Oncol. 2021 04; 15(4):1054-1068.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|